JP2013519683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519683A5 JP2013519683A5 JP2012553046A JP2012553046A JP2013519683A5 JP 2013519683 A5 JP2013519683 A5 JP 2013519683A5 JP 2012553046 A JP2012553046 A JP 2012553046A JP 2012553046 A JP2012553046 A JP 2012553046A JP 2013519683 A5 JP2013519683 A5 JP 2013519683A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- pharmaceutically acceptable
- composition according
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30347210P | 2010-02-11 | 2010-02-11 | |
| US61/303,472 | 2010-02-11 | ||
| PCT/US2011/024583 WO2011100585A1 (en) | 2010-02-11 | 2011-02-11 | Secondary structure stabilized nmda receptor modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016080043A Division JP6328169B2 (ja) | 2010-02-11 | 2016-04-13 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519683A JP2013519683A (ja) | 2013-05-30 |
| JP2013519683A5 true JP2013519683A5 (enExample) | 2014-03-27 |
| JP5928828B2 JP5928828B2 (ja) | 2016-06-01 |
Family
ID=44368160
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553046A Active JP5928828B2 (ja) | 2010-02-11 | 2011-02-11 | Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用 |
| JP2016080043A Expired - Fee Related JP6328169B2 (ja) | 2010-02-11 | 2016-04-13 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
| JP2018079295A Withdrawn JP2018119004A (ja) | 2010-02-11 | 2018-04-17 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
| JP2020046041A Pending JP2020117510A (ja) | 2010-02-11 | 2020-03-17 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016080043A Expired - Fee Related JP6328169B2 (ja) | 2010-02-11 | 2016-04-13 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
| JP2018079295A Withdrawn JP2018119004A (ja) | 2010-02-11 | 2018-04-17 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
| JP2020046041A Pending JP2020117510A (ja) | 2010-02-11 | 2020-03-17 | Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9101612B2 (enExample) |
| EP (1) | EP2542254B1 (enExample) |
| JP (4) | JP5928828B2 (enExample) |
| CN (2) | CN102933226A (enExample) |
| AU (1) | AU2011215704B2 (enExample) |
| BR (1) | BR112012020142A2 (enExample) |
| CA (1) | CA2789331C (enExample) |
| ES (1) | ES2706063T3 (enExample) |
| IL (1) | IL221400A (enExample) |
| MX (1) | MX2012009388A (enExample) |
| RU (1) | RU2566821C2 (enExample) |
| SG (3) | SG10201501050RA (enExample) |
| WO (1) | WO2011100585A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5702288B2 (ja) | 2008-09-18 | 2015-04-15 | ノースウエスタン ユニバーシティ | Ｎｍｄａレセプターモジュレータ及びその用途 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| AU2011215704B2 (en) * | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| AU2014212501A1 (en) | 2013-01-29 | 2015-07-30 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CA2899010A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| LT2951183T (lt) * | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas |
| MX375286B (es) | 2013-01-29 | 2025-03-06 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| CA2898863A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CA2928701A1 (en) * | 2013-10-28 | 2015-05-07 | Naurex, Inc. | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| KR20160144499A (ko) * | 2014-04-25 | 2016-12-16 | 노렉스, 인크. | 신경활성 펩타이드의 안정한 조성물 |
| WO2015200322A1 (en) * | 2014-06-23 | 2015-12-30 | Northwestern University | Methods of treating or ameliorating migraine |
| EP3916003A1 (en) * | 2014-07-24 | 2021-12-01 | Naurex, Inc. | N-methyl-d-aspartate receptor modulators and methods of making and using same |
| EA201890946A1 (ru) | 2015-10-14 | 2018-09-28 | Бристол-Маерс Сквибб Компани | Селективные антагонисты nr2b |
| CA3001894A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| CA3013329A1 (en) * | 2016-02-01 | 2017-08-10 | M. Amin Khan | Processes for synthesis of dipyrrolidine peptide compounds |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP6823083B2 (ja) | 2016-05-19 | 2021-01-27 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| PE20190504A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
| MX385336B (es) | 2016-08-01 | 2025-03-18 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| EA201990424A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| ES2974090T3 (es) | 2016-08-01 | 2024-06-25 | Tenacia Biotechnology Hong Kong Co Ltd | Moduladores de NMDA de espirolactama y métodos de uso de los mismos |
| JP7210599B2 (ja) | 2018-01-31 | 2023-01-23 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| AU2019215049A1 (en) * | 2018-01-31 | 2020-09-17 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CN110003309B (zh) * | 2019-04-09 | 2021-09-10 | 北京广为医药科技有限公司 | 调节nmda受体活性的化合物、其药物组合物及用途 |
| JP2022543772A (ja) * | 2019-08-01 | 2022-10-14 | アプティニックス インコーポレイテッド | Ｎｍｄａ受容体と相互作用する抗体のレベル上昇に関連する障害を治療する方法 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| CN114957444B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar的nr1亚基缺失突变体、突变体细胞及构建方法和应用 |
| CN114957445B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683221A (en) | 1986-01-09 | 1987-07-28 | Scripps Clinic And Research Foundation | Lymphocyte-activating polypeptides |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5350769A (en) | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
| JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| NZ332347A (en) | 1996-06-07 | 2000-05-26 | Zeneca Ltd | Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues |
| US5959075A (en) | 1996-08-02 | 1999-09-28 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| US6897028B1 (en) | 1997-07-07 | 2005-05-24 | Florida State University | Identification of molecular targets |
| WO1999002733A1 (en) * | 1997-07-07 | 1999-01-21 | Florida State University | Identification of molecular targets |
| AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| US6902886B1 (en) | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| AU1724000A (en) | 1998-11-12 | 2000-05-29 | Nyxis, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| CA2398250A1 (en) | 2000-02-01 | 2001-08-09 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
| WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| AU2001271366A1 (en) | 2000-06-22 | 2002-01-02 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| WO2002072005A2 (en) | 2001-03-07 | 2002-09-19 | University Of Utah Research Foundation | Linear y-carboxyglutamate rich conotoxins |
| AU2002255705A1 (en) | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| JP2004531731A (ja) | 2001-05-31 | 2004-10-14 | ザ トラスティーズ オブ プリンストン ユニバーシテイ | Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ |
| WO2003010540A1 (en) | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| EP1660634A4 (en) | 2003-08-08 | 2009-02-18 | Burnham Inst | P16-mediated regulation of NMDA receptors |
| WO2005020973A2 (en) | 2003-08-29 | 2005-03-10 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| AU2006282942B2 (en) * | 2005-08-26 | 2012-07-26 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
| US8507439B2 (en) * | 2005-08-29 | 2013-08-13 | Angela Shashoua | Neuroprotective and neurorestorative method and compositions |
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| MX2009002921A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| KR101647520B1 (ko) | 2008-08-07 | 2016-08-10 | 에프. 호프만-라 로슈 아게 | 거대환식 화합물의 제조 방법 |
| JP5702288B2 (ja) | 2008-09-18 | 2015-04-15 | ノースウエスタン ユニバーシティ | Ｎｍｄａレセプターモジュレータ及びその用途 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| CN102316886B (zh) | 2008-12-15 | 2014-06-18 | 可尔必思株式会社 | 抗皮肤老化肽 |
| WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| DK2985032T3 (en) | 2009-10-05 | 2019-04-15 | Univ Northwestern | GLYX TO USE TO TREAT ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE |
| PH12012501222A1 (en) * | 2009-12-17 | 2012-11-05 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| AU2011215704B2 (en) | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
| EA029999B1 (ru) | 2011-04-27 | 2018-06-29 | Нортвестерн Юниверсити | Способы лечения аутизма |
| US8795919B2 (en) | 2011-11-29 | 2014-08-05 | Societe BIC & Sanyo Electric Co., Ltd. | Fuel cell layer |
-
2011
- 2011-02-11 AU AU2011215704A patent/AU2011215704B2/en active Active
- 2011-02-11 CA CA2789331A patent/CA2789331C/en active Active
- 2011-02-11 SG SG10201501050RA patent/SG10201501050RA/en unknown
- 2011-02-11 ES ES11761468T patent/ES2706063T3/es active Active
- 2011-02-11 BR BR112012020142-5A patent/BR112012020142A2/pt not_active Application Discontinuation
- 2011-02-11 MX MX2012009388A patent/MX2012009388A/es active IP Right Grant
- 2011-02-11 JP JP2012553046A patent/JP5928828B2/ja active Active
- 2011-02-11 CN CN2011800146633A patent/CN102933226A/zh active Pending
- 2011-02-11 SG SG10201811584RA patent/SG10201811584RA/en unknown
- 2011-02-11 CN CN201510222007.2A patent/CN105037492A/zh active Pending
- 2011-02-11 US US13/578,189 patent/US9101612B2/en active Active
- 2011-02-11 RU RU2012138710/04A patent/RU2566821C2/ru active
- 2011-02-11 WO PCT/US2011/024583 patent/WO2011100585A1/en not_active Ceased
- 2011-02-11 SG SG2012059358A patent/SG183265A1/en unknown
- 2011-02-11 EP EP11761468.5A patent/EP2542254B1/en active Active
-
2012
- 2012-08-09 IL IL221400A patent/IL221400A/en active IP Right Grant
-
2015
- 2015-05-14 US US14/712,481 patent/US9593145B2/en active Active
-
2016
- 2016-04-13 JP JP2016080043A patent/JP6328169B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-17 JP JP2018079295A patent/JP2018119004A/ja not_active Withdrawn
-
2020
- 2020-03-17 JP JP2020046041A patent/JP2020117510A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532687A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2013530958A5 (enExample) | ||
| JP2015504870A5 (enExample) | ||
| JP2012107057A5 (enExample) | ||
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
| EP2881384A8 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| ES2723277T3 (es) | Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| JP2011168603A5 (enExample) | ||
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| JP2011105738A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2015503422A5 (enExample) | ||
| EP4643945A3 (en) | Neuroactive steroids and methods of use thereof | |
| EP2484673A3 (en) | A process for the resolution of (R,S)-nicotine | |
| ES2560676T3 (es) | Combinación farmacéutica para el tratamiento del dolor | |
| CY1118662T1 (el) | Νεες δικυκλικες πυριδινονες | |
| JP2012519182A5 (enExample) | ||
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| IN2015DN00845A (enExample) | ||
| EA201300990A1 (ru) | Парентеральное введение тапентадола | |
| EA201792597A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |